XTLB

XTL Biopharmaceuticals Ltd.

2.22 USD
-0.37 (-14.29%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

XTL Biopharmaceuticals Ltd. stock is down -10.48% since 30 days ago. The next earnings date is Aug 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 47.37% of the previous 18 July’s closed higher than June.

About XTL Biopharmaceuticals Ltd.

The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. is headquartered in Ramat Gan, Israel.